WO1996025933A3 - Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks - Google Patents

Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks Download PDF

Info

Publication number
WO1996025933A3
WO1996025933A3 PCT/JP1996/000394 JP9600394W WO9625933A3 WO 1996025933 A3 WO1996025933 A3 WO 1996025933A3 JP 9600394 W JP9600394 W JP 9600394W WO 9625933 A3 WO9625933 A3 WO 9625933A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
prevention
treatment
carboxylic acid
acid compounds
Prior art date
Application number
PCT/JP1996/000394
Other languages
French (fr)
Other versions
WO1996025933A2 (en
Inventor
Zen-Ichi Terashita
Kaneyoshi Kato
Takenobu Sohma
Original Assignee
Takeda Chemical Industries Ltd
Terashita Zen Ichi
Kaneyoshi Kato
Takenobu Sohma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Terashita Zen Ichi, Kaneyoshi Kato, Takenobu Sohma filed Critical Takeda Chemical Industries Ltd
Priority to AU47309/96A priority Critical patent/AU4730996A/en
Priority to EP96903205A priority patent/EP0810862A2/en
Publication of WO1996025933A2 publication Critical patent/WO1996025933A2/en
Publication of WO1996025933A3 publication Critical patent/WO1996025933A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition for treating a transient ischemic attack which comprises a compound of formula (I), wherein R1 is a pyridyl group, R2 is a phenyl, thienyl, furyl, naphthyl, benzothienyl or pyridyl group, which may be substituted with a lower alkoxy group, a lower alkyl group, a halogen atom, trifluoromethyl group, a lower alkenyl group or/and methylenedioxy group, R3 is hydrogen atom or a lower alkyl group, and l is an integer of 0 to 6, Y is sulfur atom, methylene group or a group of formula (a), wherein R4 is hydrogen atom or acetyl group, and m is 0 or 1, or a pharmaceutically acceptable salt.
PCT/JP1996/000394 1995-02-22 1996-02-21 Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks WO1996025933A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU47309/96A AU4730996A (en) 1995-02-22 1996-02-21 Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks
EP96903205A EP0810862A2 (en) 1995-02-22 1996-02-21 Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3396095 1995-02-22
JP7/33960 1995-02-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US66931696A A-371-Of-International 1995-02-22 1996-07-09
US09/769,440 Continuation US20010003751A1 (en) 1995-02-22 2001-01-26 Pharmaceutical composition for treating transient ischemic attack

Publications (2)

Publication Number Publication Date
WO1996025933A2 WO1996025933A2 (en) 1996-08-29
WO1996025933A3 true WO1996025933A3 (en) 1996-10-17

Family

ID=12401068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/000394 WO1996025933A2 (en) 1995-02-22 1996-02-21 Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks

Country Status (4)

Country Link
EP (1) EP0810862A2 (en)
AU (1) AU4730996A (en)
CA (1) CA2213507A1 (en)
WO (1) WO1996025933A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4194095B2 (en) * 2001-09-11 2008-12-10 旭化成ファーマ株式会社 Pharmaceutical composition for prevention / treatment of cerebrovascular disorder and heart disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098690A2 (en) * 1982-06-14 1984-01-18 Takeda Chemical Industries, Ltd. Vinyl carboxylic acid derivatives, their production and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098690A2 (en) * 1982-06-14 1984-01-18 Takeda Chemical Industries, Ltd. Vinyl carboxylic acid derivatives, their production and use

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AL-WATHIQUI, M. ET AL: "Cyclical carotid artery flow reduction in conscious dogs: Effect of a new thromboxane receptor antagonist", AMERICAN HEART JOURNAL, vol. 116, no. 6 pt. 1, December 1988 (1988-12-01), pages 1482 - 1487, XP000579143 *
ARCH JPN CHIR, 55 (1). 1986. 251-259. *
BRAIN NERVE, 1986, 38/10 (925-931), JAPAN *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; OKAMOTO S ET AL: "TREATMENT OF OCCLUSIVE CEREBROVASCULAR DISEASE WITH A SELECTIVE THROMBOXANE A-2 SYNTHETASE INHIBITOR", XP002010663 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; IMURA Y. ET AL: "Protective effect of CV-4151 (isbogrel) on arachidonic acid-induced transient cerebral ischemia in dogs", XP002010662 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; KATAYAMA Y. ET AL: "Protective effect of thromboxane Asub 2 synthetase inhibitor (trapidil) on acutely-induced cerebral ischemia", XP002010664 *
FUJIMURA M ET AL: "Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits.", THROMB RES, MAY 1 1993, 70 (3) P233-44, UNITED STATES, XP000579091 *
JAPANESE PHARMACOLOGY AND THERAPEUTICS, 1995, 23/4 (45-52), JAPAN *
SATOH, H. ET AL: "Protective effects of KW-3635, a thromboxane A2 antagonist on arachadonic acid-induced transient cerebral ischemia in dogs", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 65, no. 1, May 1994 (1994-05-01), pages 45-50, XP000578984 *

Also Published As

Publication number Publication date
WO1996025933A2 (en) 1996-08-29
EP0810862A2 (en) 1997-12-10
CA2213507A1 (en) 1996-08-29
AU4730996A (en) 1996-09-11

Similar Documents

Publication Publication Date Title
CO5280070A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS OF INDAZOL AND METHODS TO MEASURE OR INHIBIT THE CELL PROLIFERATION
EA200000731A1 (en) ALPHA-AMINOAMID DERIVATIVES, USEFUL AS ANALGETIC AGENTS
CA2243199A1 (en) Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
CA2073981A1 (en) 2-arylthiazole derivatives and pharmaceutical composition thereof
CA2328780A1 (en) Dihydropyrimidines
CA2315050A1 (en) Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
WO2003039451A3 (en) Thiazole pyridazinones as adenosine antagonists
BR0309447A (en) Compound, agent, processes for their preparation, and for combating unwanted plant growth, and use of the compound
DE69505968D1 (en) AZOLIDINDION DERIVATIVES AND THEIR USE AS ANTI-HYPERGLYCEMAS
EA200101077A1 (en) COMPOSITION FOR PREVENTION OR TREATMENT OF WEAKNESS, INCLUDING A HYDROXICORIC ACID DERIVATIVE OR EXTRACT OF ANGELICAE GENERA PLANT, CONTAINING IT
FR2741619B1 (en) NOVEL 2,3,5-TRIMETHYL-4-HYDROXY-ANILIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
KR920009394A (en) Synergistic HIV Reverse Transcriptase Inhibitor
CA2067758A1 (en) Piperidine and pyrrolidine derivatives
CA2357038A1 (en) Medical compositions comprising 1,4-benzothiazepine derivatives for the treatment of atrial fibrillation
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition
CA2016665A1 (en) Rhodanine derivatives and pharmaceutical compositions
IL114969A0 (en) Carboxamide compounds
WO1996025933A3 (en) Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks
EP0335979A4 (en) Thienopyrimidine derivatives
MXPA02011352A (en) Novel benzofuran derivatives.
ES2170804T3 (en) DERIVATIVES OF DIHIDRO-2,3-BENZODIAZEPINA.
RS49832B (en) Method for preparing alkyloxy furanone derivatives, compounds obtained by sajd method and use of sajd compounds
KR880008999A (en) 3-aryl-5-alkylthio-4H-1,2,4-triazole
MY133207A (en) Substituted benzolactam compaunds
SE9802546D0 (en) Medicinal product and method for treatment and prevention of dyskinesia

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 669316

Date of ref document: 19960709

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996903205

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2213507

Country of ref document: CA

Ref country code: CA

Ref document number: 2213507

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996903205

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996903205

Country of ref document: EP